Tacrine (CognexTM, Natick, MA, USA), an AChE inhibitor, was the first drug approved by the Food and Drug Administration, in 1993, for the treatment of AD, but due to its hepato-toxic potential, the drug was withdrawn from the market in 2012 [40]. The gene discussed is ACHE; the disease is Alzheimer disease.